CNS-Diagnostics: Chimera Biotec Starts Study on Novel Biomarker Detection for Alzheimer's Disease
European Commission supports study including 11 centres from 6 European countries
Abnormalities in the processing of the beta amyloid protein are an important characteristic of Alzheimer's disease. Moreover, recent studies have shown that beta amyloid precursor oligomers play an important role in the early stage of Alzheimer's disease.
"To describe and characterize these oligomers will be one of the most important advancements in the understanding of Alzheimer's disease in the next years" summarizes Jan Detmers, Chimera Biotec´s Business Development Director. Currently, many companies develop drugs that influence the processing of the beta amyloid peptide and its precursors. In this study, it will be investigated whether the oligomers can be used as a diagnostic marker of Alzheimer's disease and whether it can be used to measure the effect of drug treatments.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.